Join the Celgene Believers

Psoriasis? Huh? Celgene's (CELG - commentary - Cramer's Take) got something that prevents the heartbreak of psoriasis? No wonder the stock is ramping again.

Some stocks get tons of respect, even if it is undeserved, stocks like Johnson & Johnson (JNJ - commentary - Cramer's Take). But others get respect in increments.

That's Celgene. I got behind this stock about 100% ago because I simply took management at face value when they said they had more in the pipe then just medicines to fight rare blood disorders. As one test after another shows that Celgene compounds combat many different kinds of disorders that affect millions of people, the stock climbs nicely.

Now with this psoriasis drug, the believers join daily. We get another 52-week high.

To me this stock, along with Gilead (GILD - commentary - Cramer's Take), remains the pick of the biotech litter.

They do go down intraday and sometimes even close down. That's your chance.

Random musings: If you love following stocks as much as I do and want to help me help people make money, you're someone I need. I'm looking for an experienced research assistant based in the New York metro area to help me out. (CFAs welcome.) Please send your resumé and cover letter to [e-mail], with "research assistant" in the subject line.

At the time of publication, Cramer had no positions in any of the stocks mentioned in this post.

ALL JIM CRAMER BLOG ENTRIES | POST A COMMENT | READ COMMENTS  

---

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click here to order his book, "Real Money: Sane Investing in an Insane World," click here to get his second book, "You Got Screwed!" and click here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.